AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).

Abstract

elbion (formerly ASTA Medica) and GlaxoSmithKline are developing an inhaled formulation of AWD-12-281 for the potential treatment of chronic obstructive pulmonary disease (COPD). By May 2005, phase II trials of this 5-hydroxyindole PDE4 inhibitor for COPD were ongoing.

• Authors: Hans-Jürgen Gutke, Jan-Hinrich Guse, Moussa Khobzaoui, Thejavathi Renukappa-Gutke, Michael Burnet
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 6 Issue 11 Pg. 1149-58 (Nov 2005) ISSN: 1472-4472 [Print] England
• PMID: 16312137 (Publication Type: Journal Article, Review)

Chemical References

• AWD 12-281
• Amides
• Aminopyridines
• Benzamides
• Cyclopropanes
• Indoles
• Lipopolysaccharides
• Phosphodiesterase Inhibitors
• Roflumilast
• Ovalbumin
• 3',5'-Cyclic-AMP Phosphodiesterases
• Cyclic Nucleotide Phosphodiesterases, Type 4

Topics

• 3',5'-Cyclic-AMP Phosphodiesterases (antagonists & inhibitors)
• Administration, Inhalation
• Administration, Topical
• Amides (administration & dosage, pharmacokinetics, therapeutic use)
• Aminopyridines (chemistry)
• Animals
• Benzamides (chemistry)
• Clinical Trials as Topic
• Cyclic Nucleotide Phosphodiesterases, Type 4
• Cyclopropanes (chemistry)
• Dermatitis, Atopic (drug therapy)
• Disease Models, Animal
• Drug Evaluation, Preclinical
• Humans
• Indoles (administration & dosage, pharmacokinetics, therapeutic use)
• Inflammation (chemically induced, drug therapy)
• Lipopolysaccharides
• Ovalbumin
• Phosphodiesterase Inhibitors (administration & dosage, pharmacokinetics, therapeutic use)
• Psoriasis (drug therapy)
• Pulmonary Disease, Chronic Obstructive (drug therapy)
• Respiratory Tract Diseases (chemically induced, drug therapy)
• Structure-Activity Relationship